View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Hydroxychloroquine fails to show benefit in Covid-19 study

Data from a large-scale clinical study conducted by Columbia University Irving Medical Center in the US showed that Covid-19 patients treated with hydroxychloroquine did not experience better performance than those who did not receive the drug.

Overall, 346 patients went on to develop respiratory failure, 180 were intubated and 166 died without intubation. The findings revealed that patients on hydroxychloroquine had the same risk of intubation or death as those who were not treated with the drug.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena